Our results suggest that the immunoproteasome may play a pathogenic role in ITP, and demonstrate that the co-inhibition of LMP2 and LMP7 is a novel potential therapeutic strategy for the treatment of ITP. This evidence concerns the gene PSMB9 and autoimmune thrombocytopenic purpura.